Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation
ObjectivesRezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus an...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1574780/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850141700976017408 |
|---|---|
| author | Juan Hong Xiaohui Zeng Wenjun Chen Ziyuan Zhou Yuming He Jun Meng Lihui Ouyang |
| author_facet | Juan Hong Xiaohui Zeng Wenjun Chen Ziyuan Zhou Yuming He Jun Meng Lihui Ouyang |
| author_sort | Juan Hong |
| collection | DOAJ |
| description | ObjectivesRezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.MethodsA Markov model with three health states was developed to evaluate the health and economic outcomes of first-line treatment for high-volume mHSPC. Efficacy data were sourced from the CHART trial. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. To address modeling uncertainties, one-way sensitivity analysis and probabilistic sensitivity analysis were performed.ResultsCompared with bicalutamide plus ADT, rezvilutamide plus ADT resulted in an additional 2.16 QALYs, with an ICER of $39,122.16/QALY. At a willingness-to-pay (WTP) threshold of three times the gross domestic product per capita in China for 2023 ($37,256.3/QALY), the probability of cost-effectiveness for rezvilutamide plus ADT was 30%. One-way sensitivity analysis revealed that the results were most sensitive to the cost of rezvilutamide. Scenario analysis indicated that rezvilutamide could be considered cost-effective if priced below $705.46 per cycle.ConclusionFrom the perspective of Chinese payers, rezvilutamide plus ADT appears to be a less cost-effective strategy compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China. |
| format | Article |
| id | doaj-art-ab3c9811c0da4ccbb8ada0323b056aeb |
| institution | OA Journals |
| issn | 2296-2565 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj-art-ab3c9811c0da4ccbb8ada0323b056aeb2025-08-20T02:29:20ZengFrontiers Media S.A.Frontiers in Public Health2296-25652025-05-011310.3389/fpubh.2025.15747801574780Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluationJuan Hong0Xiaohui Zeng1Wenjun Chen2Ziyuan Zhou3Yuming He4Jun Meng5Lihui Ouyang6Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, ChinaDepartment of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaSchool of Pharmacy, Guangdong Medical University, Dongguan, ChinaDepartment of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, ChinaDepartment of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, ChinaObjectivesRezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.MethodsA Markov model with three health states was developed to evaluate the health and economic outcomes of first-line treatment for high-volume mHSPC. Efficacy data were sourced from the CHART trial. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were calculated. To address modeling uncertainties, one-way sensitivity analysis and probabilistic sensitivity analysis were performed.ResultsCompared with bicalutamide plus ADT, rezvilutamide plus ADT resulted in an additional 2.16 QALYs, with an ICER of $39,122.16/QALY. At a willingness-to-pay (WTP) threshold of three times the gross domestic product per capita in China for 2023 ($37,256.3/QALY), the probability of cost-effectiveness for rezvilutamide plus ADT was 30%. One-way sensitivity analysis revealed that the results were most sensitive to the cost of rezvilutamide. Scenario analysis indicated that rezvilutamide could be considered cost-effective if priced below $705.46 per cycle.ConclusionFrom the perspective of Chinese payers, rezvilutamide plus ADT appears to be a less cost-effective strategy compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China.https://www.frontiersin.org/articles/10.3389/fpubh.2025.1574780/fullcost-effectivenessrezvilutamidebicalutamidehigh-volume mHSPCMarkov model |
| spellingShingle | Juan Hong Xiaohui Zeng Wenjun Chen Ziyuan Zhou Yuming He Jun Meng Lihui Ouyang Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation Frontiers in Public Health cost-effectiveness rezvilutamide bicalutamide high-volume mHSPC Markov model |
| title | Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation |
| title_full | Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation |
| title_fullStr | Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation |
| title_full_unstemmed | Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation |
| title_short | Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov’s model-based evaluation |
| title_sort | cost effectiveness analysis of rezvilutamide versus bicalutamide and androgen deprivation therapy in patients with high volume metastatic hormone sensitive prostate cancer a markov s model based evaluation |
| topic | cost-effectiveness rezvilutamide bicalutamide high-volume mHSPC Markov model |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1574780/full |
| work_keys_str_mv | AT juanhong costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT xiaohuizeng costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT wenjunchen costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT ziyuanzhou costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT yuminghe costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT junmeng costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation AT lihuiouyang costeffectivenessanalysisofrezvilutamideversusbicalutamideandandrogendeprivationtherapyinpatientswithhighvolumemetastatichormonesensitiveprostatecanceramarkovsmodelbasedevaluation |